SANDRA AUNG, Ph.D.
SENIOR VICE PRESIDENT, CHIEF CLINICAL DEVELOPMENT OFFICER
Dr. Aung has over 20 years of experience in the pharmaceutical and biotechnology industry, and has led teams and projects in companies of different sizes.
VICE PRESIDENT, PRODUCT ENGINEERING
Mr. Silverman joins OncoSec with over two decades of electroporation device quality and manufacturing experience.
ROBERT J. DELAVERSANO, C.P.A.
VICE PRESIDENT, FINANCE
Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.
BRIDGET O'KEEFFE, Ph.D.
VICE PRESIDENT, CLINICAL DEVELOPMENT
Dr. O’Keeffe is a biotech industry veteran who brings more than 15 years of clinical development and leadership experience largely focused on Oncology, including the combination of cytokines and check-point inhibitors.
VICE PRESIDENT, BUSINESS DEVELOPMENT
Mr. Smith brings over 12 years of business development leadership experience in the life sciences industry.
ROB SCHINAGL, Ph.D.
VICE PRESIDENT, PROGRAM & ALLIANCE MANAGEMENT
Dr. Schinagl has more than 25 years of program and alliance management experience in the pharmaceutical, biotech, and device industries.
Board of Directors
LINDA SHI, M.D., Ph.D.
Dr. Linda Shi is the deputy president and Chief Medical officer of Grand Pharma (China), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong.
HERBERT KIM LYERLY, M.D.
Dr. Herbert Kim Lyerly is the George Barth Geller Professor of Cancer Research, professor of surgery, immunology and pathology, and director of the surgical sciences applied therapeutics section at Duke University.
Chao Zhou is currently the Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, a public company listed on the Hong Kong stock exchange.
KEVIN R. SMITH
Kevin R. Smith is currently the Chief Executive Officer of Sirtex Medical US Holdings, Inc. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur.
JIM DEMESA, M.D., MBA
Dr. DeMesa has served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development.
Joon Kim is a highly accomplished attorney and partner in Lee & Ko’s Corporate, International Litigation and Dispute Resolution, and White Collar Crime Practice Groups. Mr. Kim advises clients, both domestic and international, on a broad range of litigation, dispute-resolution and transactional matters.
Scientific Advisory Board
RICHARD HELLER, Ph.D.
Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.
IACOB MATHIESEN, Ph.D.
Dr. Mathiesen has a Ph.D. from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.
SOLDANO FERRONE, M.D., Ph.D.
Dr. Ferrone leads a research program focused on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction.
Clinical Advisory Board
ALAIN ALGAZI M.D.
Associate Professor, Department of Medicine (Hematology / Oncology), UCSF Program Leader, UCSF Head and Neck Medical Oncology Melanoma Specialist, UCSH Medical Center
ROBERT H.I. ANDTBACKA, M.D., CM, FACS, FRCSC
Associate Professor, Surgical Oncology Department of Surgery University of Utah, Co-Director Melanoma Program, Co-Director Melanoma Clinical Research Program Huntsman Cancer Institute
AXEL HAUSCHILD, M.D., Ph.D.
Professor of Dermatology, Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany
GEORGINA LONG, BSc, Ph.D., MBBS, FRACP
Conjoint Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, University of Sydney, Royal North Shore Hospital
PAMELA MUNSTER, M.D.
Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center
WALTER J URBA, M.D., Ph.D.
Medical Oncologist; director of cancer research; co-director, Providence Melanoma Programy